Montelukast Bgr (Montelukast)

Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1. This blocks leukotriene D4 from binding, which in turn reduces bronchoconstriction, mucus secretion, and inflammatory cell recruitment, leading to improved airway patency and decreased allergic inflammation.

The specific dose of Montelukast Bgr is determined by the prescribing clinician based on the patient’s age, weight, severity of disease, and response to therapy. Healthcare professionals follow approved labeling and clinical guidelines when selecting the appropriate regimen.

Safety data for Montelukast in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk. Caution is also advised during breastfeeding, and a healthcare provider should evaluate the risk‑benefit profile.

To place an order, submit an enquiry on the Montelukast Bgr product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑exacerbated respiratory disease or those who prefer a non‑inhaled option, though it is generally used as add‑on therapy rather than a sole replacement for inhaled steroids.

Montelukast Bgr should be stored at ambient temperature below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Montelukast Bgr is taken orally, usually once daily in the evening with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious adverse events, though rare, include angioedema, severe allergic reactions, and neuropsychiatric effects such as mood changes, depression, or suicidal thoughts. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Bgr is contraindicated in individuals with a known hypersensitivity to montelukast or any of its excipients. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in those for whom the risk‑benefit assessment is unfavorable.